Aluminum oxide

Identification

Generic Name

Aluminum oxide

DrugBank Accession Number

DB11342

Background

Aluminum oxide has a chemical formula Al2O3. It is amphoteric in nature, and is used in various chemical, industrial and commercial applications. It is considered an indirect additive used in food contact substances by the FDA.

Type

Small Molecule

Groups

Approved

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Aluminum oxide (DB11342)

×

Close

Weight

Average: 101.96
Monoisotopic: 101.9478209

Chemical Formula

Al₂O₃

Synonyms

• Aluminium oxide

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Used in combination as diagnostic agent	Bleeding	Combination Product in combination with: Sodium molybdate (DB14496), Technetium Tc-99m pertechnetate (DB09314)	••••••••••••			••••••••
Used in combination as diagnostic agent	Brain swelling	Combination Product in combination with: Sodium molybdate (DB14496), Technetium Tc-99m pertechnetate (DB09314)	••••••••••••			••••••••
Used in combination as diagnostic agent	Ectopic intestinal mucosa	Combination Product in combination with: Technetium Tc-99m pertechnetate (DB09314), Sodium molybdate (DB14496)	••••••••••••			••••••••
Used in combination as diagnostic agent	Meckel diverticulum	Combination Product in combination with: Sodium molybdate (DB14496), Technetium Tc-99m pertechnetate (DB09314)	••••••••••••			••••••••
Used in combination as diagnostic agent	Occult gi bleeding	Combination Product in combination with: Sodium molybdate (DB14496), Technetium Tc-99m pertechnetate (DB09314)	••••••••••••			••••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Carbamazepine	Aluminum oxide can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chenodeoxycholic acid	Aluminum oxide can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic Acid	Aluminum oxide can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Deferasirox	Aluminum oxide can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dehydrocholic acid	Aluminum oxide can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
ALUMINIUM HYDROXIDE MIXTURE BP 4% w/w	Suspension	4 % w/w	Oral	SUNWARD PHARMACEUTICAL PRIVATE LIMITED	1989-04-21	Not applicable
ALUTACID ANTACID MIXTURE 4% w/w	Suspension	4 % w/w	Oral	ICM PHARMA PTE. LTD.	1996-03-07	Not applicable
Brasivol Fine	Cream	38.2 %	Topical	Stiefel Laboratories, Inc.	1966-12-31	2000-01-07
Brasivol Medium	Cream	52.2 %	Topical	Stiefel Laboratories, Inc.	1966-12-31	2000-01-07
Vfb Bio Peel	Powder	6.5 mg/1g	Topical	General Bio Co., Ltd.	2014-12-09	2019-09-30

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
POLGENTEC 2-120 GBQ GENERADOR DE RADIONUCLEIDOS	Aluminum oxide (2 g) + Sodium molybdate (0 GBq) + Technetium Tc-99m sodium pertechnetate (120 GBq)	Solution	Intravenous	ISOMEDIX TECHNOLOGY S.A.S.	2013-09-19	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Vfb Bio Peel	Aluminum oxide (6.5 mg/1g)	Powder	Topical	General Bio Co., Ltd.	2014-12-09	2019-09-30

Categories

ATC Codes

D10AX04 — Aluminium oxide

• D10AX — Other anti-acne preparations for topical use
• D10A — ANTI-ACNE PREPARATIONS FOR TOPICAL USE
• D10 — ANTI-ACNE PREPARATIONS
• D — DERMATOLOGICALS

Drug Categories

• Aluminium Compounds
• Aluminum Oxides
• Anti-Acne Preparations
• Anti-Acne Preparations for Topical Use
• Dermatologicals
• Metal cations
• Metal divalent cations
• Oxides
• Oxygen Compounds

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of inorganic compounds known as post-transition metal salts. These are inorganic halogenic compounds in which the heaviest metal atom is a post-transition metal.

Kingdom

Inorganic compounds

Super Class

Mixed metal/non-metal compounds

Class

Post-transition metal salts

Sub Class

Not Available

Direct Parent

Post-transition metal salts

Alternative Parents

Miscellaneous mixed metal/non-metals / Inorganic salts

Substituents

Inorganic post-transition metal salt / Inorganic salt / Miscellaneous mixed metal/non-metal

Molecular Framework

Not Available

External Descriptors

Not Available

Affected organisms

Not Available

Chemical Identifiers

UNII

LMI26O6933

CAS number

1344-28-1

InChI Key

PNEYBMLMFCGWSK-UHFFFAOYSA-N

InChI

InChI=1S/2Al.3O/q2*+3;3*-2

IUPAC Name

dialuminium(3+) ion trioxidandiide

SMILES

[O--].[O--].[O--].[Al+3].[Al+3]

References

General References

Not Available

External Links

PubChem Compound

9989226

PubChem Substance

347827970

ChemSpider

8164808

RxNav

615

ChEMBL

CHEMBL3707210

Wikipedia

Aluminium_oxide

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Suspension	Oral	4 % w/w
Cream	Topical	38.2 %
Cream	Topical	52.2 %
Solution	Intravenous
Powder	Topical	6.5 mg/1g

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
logP	-0.65	Chemaxon
pKa (Strongest Acidic)	15.7	Chemaxon
pKa (Strongest Basic)	-1.8	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	1	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	0 Å2	Chemaxon
Rotatable Bond Count	0	Chemaxon
Refractivity	13.11 m3·mol-1	Chemaxon
Polarizability	0.95 Å3	Chemaxon
Number of Rings	0	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	Yes	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Chromatographic Properties

Collision Cross Sections (CCS)

Not Available

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at December 03, 2015 16:52 / Updated at May 21, 2021 10:22